Drug intelligence / Profile preview

BXCL503

Development stage: Preclinical
Lead developer: BioXcel Therapeutics
Modality: Small Molecules

Overview

BXCL503 is an investigational small molecule drug being developed by BioXcel Therapeutics for the treatment of apathy related to dementia, including Alzheimer's disease. It is part of BioXcel's neuroscience pipeline and represents a new molecular entity distinct from their more advanced asset, BXCL501 (dexmedetomidine sublingual film). The precise mechanism of action for BXCL503 has not been publicly disclosed as of the latest updates. The drug is currently in preclinical development stages and aims to address symptoms such as apathy in dementia patients, a significant unmet need in neuropsychiatric care[2][7][9].

Beyond the preview

Go deeper on BXCL503.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BXCL503.

Explore the full profile